Second-line systemic therapy for the treatment of metastatic renal cell cancer

References

• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17(8), 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Fossa SD. Interferon in metastatic renal cell carcinoma. Semin. Oncol.27(2), 187–193 (2000).
   PubMed Web of Science ®Google Scholar
• Brauch H, Pomer S, Hieronymus T, Schadt T, Lohrke H, Komitowski D. Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p. World J. Urol.12(3), 162–168 (1994).
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol.58(3), 398–406 (2010).
   PubMed Web of Science ®Google Scholar
• Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev. Anticancer Ther.11(4), 639–649 (2011).
   PubMed Web of Science ®Google Scholar
• Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, Haase VH. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel–Lindau disease-associated vascular tumors in mice. Mol. Cell. Biol.25(8), 3163–3172 (2005).
   PubMed Web of Science ®Google Scholar
• Kluger HM, Siddiqui SF, Angeletti C et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab. Invest.88(9), 962–972 (2008).
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol.22(20), 7004–7014 (2002).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27(20), 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep.9(2), 115–119 (2007).
   PubMedGoogle Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol.8(11), 975–984 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol.27(27), 4462–4468 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R. D.11(2), 113–126 (2011).
   PubMedGoogle Scholar
• Rini BI, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of Phase III AXIS trial. ASCO Meeting Abstracts29(Suppl. 15), 4503 (2011).
   Google Scholar
• Bhargava P, Esteves B, Al-Adhami M et al. Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol.28(15), 4599 (2010).
   Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26(33), 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon α versus interferon α monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol.28(13), 2137–2143 (2010).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus interferon α-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol.28(13), 2144–2150 (2010).
   PubMed Web of Science ®Google Scholar
• Négrier S, Gravis G, Pérol D et al. Temsirolimus and bevacizumab, or sunitinib, or interferon α and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised Phase 2 trial. Lancet Oncol.12(7), 673–680 (2011).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer116(18), 4256–4265 (2010).
   PubMed Web of Science ®Google Scholar
• Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A Phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer115(11), 2438–2446 (2009).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24(16), 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol.178(5), 1883–1887 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295(21), 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Bellmunt J. Sunitinib in advanced renal cell carcinoma: clinical evidence. Eur. Urol. Suppl.7(9), 585–592 (2008).
   Web of Science ®Google Scholar
• Porta C, Procopio G, Cartenì G et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int.108(8B), E250–E257 (2011).
   PubMed Web of Science ®Google Scholar
• Herrmann E, Marschner N, Grimm M et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J. Urol.29(3), 361–366 (2011).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, De La Motte Rouge T, Harzstark AL et al. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): five-year (yr) overall survival (OS) data from a Phase II trial. ASCO Meeting Abstracts29(Suppl. 15), 4547 (2011).
   Google Scholar
• Bedke J, Stenzl A. Renal cell carcinoma: recent developments in diagnostics and therapy. Urologe A49(Suppl. 1), 178–184 (2010).
   PubMedGoogle Scholar
• Zhang L, Bhasin M, Schor-Bardach R et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS ONE6(4), E19144 (2011).
   PubMed Web of Science ®Google Scholar
• Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol.54(6), 1373–1378 (2008).
   PubMed Web of Science ®Google Scholar
• Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol.182(1), 29–34 (2009).
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer115(1), 61–67 (2009).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Cartenì G, Autorino R et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J. Clin. Oncol.27(27), 4469–4474 (2009).
   PubMed Web of Science ®Google Scholar
• Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol.22(8), 1812–1823 (2011).
   PubMed Web of Science ®Google Scholar
• Stadler WM, Figlin RA, Mcdermott DF et al. Safety and efficacy results of the Advanced Renal Cell Carcinoma Sorafenib expanded access program in North America. Cancer116(5), 1272–1280 (2010).
   PubMed Web of Science ®Google Scholar
• Herrmann E, Marschner N, Grimm M et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. ASCO Meeting Abstracts29(Suppl. 15), E15061 (2011).
   Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol.26(22), 3743–3748 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia JA, Hutson TE, Elson P et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer116(23), 5383–5390 (2010).
   PubMed Web of Science ®Google Scholar
• Reeves JA, Spigel DR, Daniel DB, Friedman EK, Burris HA, Hainsworth JD. Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: a Sarah Cannon Research Institute Phase II trial. ASCO Meeting Abstracts29(Suppl. 15), 4659 (2011).
   Google Scholar
• Dutcher JP, Wilding G, Hudes GR et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. ASCO Meeting Abstracts26(Suppl. 15), 5127 (2008).
   Google Scholar
• Kruck S, Bedke J, Hennenlotter J et al. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncol. Rep.23(1), 159–163 (2010).
   PubMed Web of Science ®Google Scholar
• Weikert S, Kempkensteffen C, Busch J et al. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World J. Urol. doi:10.1007/s00345-011-0676-1 (2011) (Epub ahead of print.)
   PubMed Web of Science ®Google Scholar
• Figlin RA, Calvo E, Motzer RJ et al. Everolimus in metastatic renal cell carcinoma (mRCC): subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the Phase III RECORD-1 study. ASCO Meeting Abstracts29(Suppl. 7), 304 (2011).
   Google Scholar
• Van Der Veldt AaM, Eechoute K, Gelderblom H et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res.17(3), 620–629 (2011).
   PubMed Web of Science ®Google Scholar
• Xu CF, Bing NX, Ball HA et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J. Clin. Oncol.29(18), 2557–2564 (2011).
   PubMed Web of Science ®Google Scholar
• Garcia-Donas J, Esteban E, Leandro-García LJ et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol.12(12), 1143–1150 (2011).
   PubMed Web of Science ®Google Scholar
• Patard JJ, Pignot G, Escudier B et al. ICUD-EAU international consultation on kidney cancer 2010: treatment of metastatic disease. Eur. Urol.60(4), 684–690 (2011).
   PubMed Web of Science ®Google Scholar